The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 06, 2026

Filed:

Aug. 15, 2019
Applicant:

University of Florida Research Foundation, Inc., Gainesville, FL (US);

Inventors:

Elias Sayour, Gainesville, FL (US);

Duane Mitchell, Gainesville, FL (US);

Attorney:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/69 (2017.01); A61K 9/00 (2006.01); A61K 9/127 (2025.01); A61K 35/15 (2025.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 47/18 (2017.01); A61P 35/00 (2006.01); C12N 5/0784 (2010.01);
U.S. Cl.
CPC ...
A61K 47/6911 (2017.08); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 35/15 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 40/19 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 40/421 (2025.01); A61K 47/186 (2013.01); A61P 35/00 (2018.01); C12N 5/0639 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55555 (2013.01);
Abstract

The present disclosure provides methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI) in a subject and methods of treating a subject with an immune checkpoint inhibitor (ICI)-resistant tumor. The methods comprise administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Also provided are methods of increasing the number of activated plasmacytoid dendritic cells (pDCs) in a subject in need thereof, comprising administering to the subject a composition comprising a liposome comprising a cationic lipid and mRNA molecules, wherein the liposome is systemically administered to the subject. Combination therapy with anti-PD-L1mAb. Related methods of treatment and methods of preparing a dendritic cell vaccine are additionally provided.


Find Patent Forward Citations

Loading…